09:29 AM EDT, 09/23/2025 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) said Tuesday that a phase 4 open-label study confirmed "robust rates" of symptomatic remission of tardive dyskinesia with once-daily Ingrezza capsules.

The analysis also showed sustained improvements in patient-reported outcomes among participants who achieved symptomatic remission, the company said.

Shares of the company were down 1% in recent Tuesday premarket activity.